nivolumab,ipilimumab
bms
['congrat', 'niche-2']
over 60% of tumors were t4a or t4b in niche-2 study. aes noted. fascinating results. congrats to patients and to excellent data #esmo22. 
Heme/Onc; NHL/HL/CLL; economics in med. Adj Professor U South Carolina; Leadership/Strategy. Host of the #HealthcareUnfiltered Podcast.  https://t.co/zNtC2QILHO